Adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in adverse events compared with placebo (high certainty).
1 finding from 1 review
Serious adverse events · Patients with moderately to severely active ulcerative colitis
Vedolizumab showed no clear difference in serious adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA may leads to higher symptomatic remission compared with placebo (low certainty).
1 finding from 1 review
Symptomatic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in symptomatic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Endoscopic remission · Patients with quiescent ulcerative colitis
Rectal 5‐ASA showed no clear difference in endoscopic remission compared with oral 5‐ASA (low certainty).
1 finding from 1 review
Relapse at 6 months Clinical Disease Activty Index more than 42 · Maintenance of remission in ulcerative colitis
Curcumin showed no clear difference in relapse at 6 months Clinical Disease Activty Index more than 42 compared with placebo (low certainty).
1 finding from 1 review
Relapse at 12 months Clinical Disease Activty Index more than 42 · Maintenance of remission in ulcerative colitis
Curcumin showed no clear difference in relapse at 12 months Clinical Disease Activty Index more than 42 compared with placebo (low certainty).
1 finding from 1 review
Disease activity · Maintenance of remission in ulcerative colitis
1 finding from 1 review
Endoscopic Index at 6 months Endoscopic Index9. Scale from: 1 to 4. · Maintenance of remission in ulcerative colitis
1 finding from 1 review
Induction of remission (timeframe not reported) ‐ Symptoms‐guided diet · people with active UC
It is very uncertain whether intervention diet changes induction of remission ‐ Symptoms‐guided diet compared with control diet (very low certainty).
1 finding from 1 review
Health‐related quality of life · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · people with active UC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · Patients with quiescent ulcerative colitis
It is very uncertain whether intervention diet changes clinical relapse at 6 months ‐ Anti‐inflammatory diet (Alberta‐based) compared with control diet (very low certainty).
3 findings from 1 review
RR 1.25 [0.42, 3.7]
1 study · 28 participants
Very low
RR 0.5 [0.15, 1.64]
1 study · 15 participants
Very low
RR 0.83 [0.6, 1.15]
2 studies · 77 participants
Low
Health related quality of life at 12 months ‐ SIBDQ ‐ Carrageenan‐free diet · Patients with quiescent ulcerative colitis
1 finding from 1 review
Adverse events · Patients with quiescent ulcerative colitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
GI adverse events · Patients with quiescent ulcerative colitis
Celecoxib showed no clear difference in GI adverse events compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · patients with induction of remission in ulcerative colitis
Trichuris suis eggs showed no clear difference in clinical remission compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement at 12 weeks · patients with induction of remission in ulcerative colitis
Trichuris suis eggs showed no clear difference in clinical improvement at 12 weeks compared with placebo (low certainty).
1 finding from 1 review
Clinical remission · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
It is very uncertain whether prebiotics changes clinical remission (14 days) compared with placebo (very low certainty).
1 finding from 1 review
Clinical improvement (Rachmilewitz index) (14 days) · people with mild‐to‐moderate disease (Rachmilewitz index) or active disease (SCCAI score of 4 to 10)
1 finding from 1 review